Progress in PF research requires patient participation

Progress in PF research requires patient participation

Today, I’m wrapping up another trip around the sun. On Oct. 4, 1957, the day I was born, the former Soviet Union launched Sputnik 1, Earth’s first artificial satellite. I’ve often wondered if there’s any relationship between my birthday and my love of space. Astronomy was my science during my…

Inhaled AP01 likely more effective, safer than Esbriet, Ofev

Treatment with AP01, Avalyn Pharma‘s experimental inhaled formulation of pirfenidone, appears to be slightly more effective for idiopathic pulmonary fibrosis (IPF) than the oral version, which is sold as Esbriet, and results in fewer side effects. AP01’s efficacy and safety profiles with progressive forms of pulmonary…

Endeavor completes enrollment in Phase 2 trial testing ENV-101

A Phase 2a clinical trial to evaluate the safety and efficacy of ENV-101 (taladegib), Endeavor BioMedicines’ oral treatment for idiopathic pulmonary fibrosis (IPF), has completed patient enrollment. Top-line data from the study (NCT04968574), which enrolled 41 adults with mild-to-moderate IPF, ages 40 and older, at sites in…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums